250 related articles for article (PubMed ID: 2466593)
1. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.
Bhakdi S; Käflein R; Halstensen TS; Hugo F; Preissner KT; Mollnes TE
Clin Exp Immunol; 1988 Dec; 74(3):459-64. PubMed ID: 2466593
[TBL] [Abstract][Full Text] [Related]
2. SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules.
Preissner KP; Podack ER; Müller-Eberhard HJ
Eur J Immunol; 1989 Jan; 19(1):69-75. PubMed ID: 2465906
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex.
Bariety J; Hinglais N; Bhakdi S; Mandet C; Rouchon M; Kazatchkine MD
Clin Exp Immunol; 1989 Jan; 75(1):76-81. PubMed ID: 2467771
[TBL] [Abstract][Full Text] [Related]
4. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
Hu VW; Shin ML
J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
[TBL] [Abstract][Full Text] [Related]
5. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
Bhakdi S; Tranum-Jensen J
J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
[TBL] [Abstract][Full Text] [Related]
6. Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues.
Halstensen TS; Mollnes TE; Brandtzaeg P
Immunology; 1988 Oct; 65(2):193-7. PubMed ID: 2461343
[TBL] [Abstract][Full Text] [Related]
7. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
Bhakdi S; Tranum-Jensen J
J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
[TBL] [Abstract][Full Text] [Related]
8. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9.
Carney DF; Koski CL; Shin ML
J Immunol; 1985 Mar; 134(3):1804-9. PubMed ID: 3968432
[TBL] [Abstract][Full Text] [Related]
9. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
Schönermark S; Filsinger S; Berger B; Hänsch GM
Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
[TBL] [Abstract][Full Text] [Related]
10. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.
Podack ER; Preissner KT; Müller-Eberhard HJ
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():89-96. PubMed ID: 6587746
[TBL] [Abstract][Full Text] [Related]
12. Isolation of homologous restriction factor from human urine. Immunochemical properties and biologic activity.
Zalman LS; Brothers MA; Müller-Eberhard HJ
J Immunol; 1989 Sep; 143(6):1943-7. PubMed ID: 2476489
[TBL] [Abstract][Full Text] [Related]
13. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
14. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization.
Tschopp J; Podack ER; Müller-Eberhard HJ
J Immunol; 1985 Jan; 134(1):495-9. PubMed ID: 3964819
[TBL] [Abstract][Full Text] [Related]
15. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass.
Salama A; Hugo F; Heinrich D; Höge R; Müller R; Kiefel V; Mueller-Eckhardt C; Bhakdi S
N Engl J Med; 1988 Feb; 318(7):408-14. PubMed ID: 3340119
[TBL] [Abstract][Full Text] [Related]
16. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
17. Molecular composition of the terminal membrane and fluid-phase C5b-9 complexes of rabbit complement. Absence of disulphide-bonded C9 dimers in the membrane complex.
Bhakdi S; Tranum-Jensen J
Biochem J; 1983 Mar; 209(3):753-61. PubMed ID: 6870789
[TBL] [Abstract][Full Text] [Related]
18. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
19. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
Morgan BP; Imagawa DK; Dankert JR; Ramm LE
J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
Stewart JL; Monahan JB; Brickner A; Sodetz JM
Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
